Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated January 13, 2012, reports on a strategic restructuring of its US General Medicines business. The restructuring is driven by the impending loss of patent exclusivity for Diovan (valsartan) in September 2012 and the termination of the ALTITUDE clinical study for Rasilez/Tekturna (aliskiren), which necessitates a reassessment of future sales potential.
Key Financial Metrics and Charges
- US Restructuring Charge: An exceptional charge of approximately USD 160 million is expected in the first quarter of 2012.
- Rasilez/Tekturna Impairment: An exceptional charge of approximately USD 900 million (approx. USD 800 million non-cash) was recognized in the fourth quarter of 2011 due to lower sales expectations following the ALTITUDE study halt.
- Program Termination Charge: An additional exceptional charge of approximately USD 160 million was recognized in the fourth quarter of 2011 for the termination of the PRT128 (elinogrel) and SMC021 (oral calcitonin) programs.
- Projected Savings: The US restructuring is planned to generate annual savings of approximately USD 450 million by 2013, with about half expected in 2012.
- Historical Context: In 2010, the Group achieved net sales of USD 50.6 billion and invested approximately USD 9.1 billion in R&D.
Material Changes and Operational Impact
The filing details a significant reduction in the US workforce to align with the new competitive landscape. The plan involves reducing the field force by approximately 1,630 positions and realigning headquarters functions, resulting in an additional reduction of approximately 330 positions, for a total of 1,960 positions. These changes are scheduled to take effect in the second quarter of 2012, with employee notifications planned for early April 2012.
Operationally, Novartis has ceased promotion of Rasilez/Tekturna for use in combination with ACE inhibitors or ARBs and is recommending against such treatment for hypertensive patients with diabetes following the ALTITUDE study termination.
Outlook, Risks, and Management Commentary
Management views the next two years as challenging for the Pharmaceuticals Division. The restructuring aims to free up resources to invest in the pipeline and focus on growth brands. David Epstein, Division Head of Novartis Pharmaceuticals, stated these are "difficult but necessary decisions" to strengthen the long-term competitive position.
Risks and Contingencies:
- Uncertainty regarding the outcome of ongoing discussions with health authorities concerning Rasilez/Tekturna.
- Potential for additional charges related to the ALTITUDE study or other factors.
- No guarantee that the projected savings from restructuring will be achieved.
- Forward-looking statements regarding future revenues and product development are subject to regulatory actions, clinical trial results, and legal proceedings.
Investor Verification Checklist
- Verify the timing and execution of the 1,960 position reductions in the US market.
- Monitor the impact of the Diovan patent expiration in September 2012 on US General Medicines revenue.
- Track the status of regulatory discussions regarding Rasilez/Tekturna and potential further sales restrictions.
- Assess whether the projected USD 450 million in annual savings by 2013 is realized as planned.
- Review future earnings reports for any additional charges related to the ALTITUDE study or pipeline adjustments.